Filing Flows › Neogenomics (NEO) › Q2 2026
Neogenomics (NEO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Jul 28, 2026
Neogenomics (NEO) reported revenue of $202M for the second quarter 2026 (Q2 2026), +11% from a year earlier and +8% from the quarter before. Operating margin was -4.8%, net earnings $2.2M (1.1% of revenue).
Neogenomics, Q2 2026: revenue $202M (+11% year over year), operating margin -4.8%, net earnings $2.2M, operating cash flow $20.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $202M | +8% | +11% |
| Operating profit | −$9.8M | — | — |
| Net earnings | $2.2M | — | — |
| Operating cash flow | $20.0M | — | -2% |
| Free cash flow | $11.7M | — | -16% |
What changed
Revenue was $201.7M in Q2 2026, up 11% year over year and up 8% from the previous quarter. Client direct billing was the largest line at 68% of revenue. Commercial insurance added $7.5M year over year (up 26%), 37% of the total change.
Gross margin was 45.6%, up 3.0 points from Q2 2025. Operating costs exceeded revenue by $9.8M, an operating margin of -4.8%. Operating expenses fell 19% while revenue rose 11%. The fastest-growing cost line was Research & development (+19%). Net earnings were $2.2M. The effective tax rate was -22.6%. Non-operating items added $11.6M, 635% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $20.0M (down 2% year over year), 892% of net earnings. Non-cash charges added back $16.2M of depreciation and amortization and $8.2M of share-based compensation. Working capital and other items used $6.7M. Capital expenditures of $8.2M left free cash flow of $11.7M.
Questions
What was Neogenomics' revenue in the second quarter 2026?
Neogenomics (NEO) reported revenue of $202M for the second quarter 2026 (Q2 2026), +11% from a year earlier and +8% from the quarter before.
Was Neogenomics profitable in the second quarter 2026?
Operating loss was $9.8M (-4.8% of revenue) and net earnings $2.2M.
Source: Neogenomics 10-Q on SEC EDGAR.